Celecoxib as a Valuable Adjuvant in Cutaneous Melanoma Treated with Trametinib

Background: Melanoma patients stop responding to targeted therapies mainly due to mitogen activated protein kinase (MAPK) pathway re-activation, phosphoinositide 3 kinase/the mechanistic target of rapamycin (PI3K/mTOR) pathway activation or stromal cell influence. The future of melanoma treatment li...

Descripción completa

Detalles Bibliográficos
Autores principales: Tudor, Diana Valentina, Bâldea, Ioana, Olteanu, Diana Elena, Fischer-Fodor, Eva, Piroska, Virag, Lupu, Mihai, Călinici, Tudor, Decea, Roxana Maria, Filip, Gabriela Adriana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122835/
https://www.ncbi.nlm.nih.gov/pubmed/33922284
http://dx.doi.org/10.3390/ijms22094387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122835/
https://www.ncbi.nlm.nih.gov/pubmed/33922284
http://dx.doi.org/10.3390/ijms22094387

Ejemplares similares